Introducing

A New Platform In Cancer Care
Robotically Assisted Sonic Therapy (RAST)
Almost 40% of us will be diagnosed with cancer at some point in our lives.
THE PROBLEM

5 year survival rates for liver and pancreatic cancers are less than 18% and 8% respectively.

Standard of care is invasive, painful, disruptive, and not effective.

More than 80% of liver and pancreatic cancer patients are non-surgical candidates, with few good options.

The impact to people is significant.
THE PROBLEM

The global cancer burden continues to surge

- Worldwide, cancer has the **biggest economic impact** of any cause of death
- Between 2005 and 2015, **global cancer cases increased by 33%**
- The global **cost of cancer will increase** from $290B in 2012 to $458B by 2030 – nearly double
THE PROBLEM

Existing oncology treatment platforms have serious limitations

SURGERY
- Invasive and Costly
  - Many patients ineligible or resistant – up to 80%
  - Long recover times
  - High complication rates

ABLATION
- Inconsistent
  - Invasive with collateral damage
  - Limited addressable patient population
  - High recurrence rates

RADIATION
- Collateral Damage
  - Long treatment courses
  - High cost and complication rates
  - Inability to retreat
OUR VISION

To lead a revolution in **non-invasive, robotically assisted** cancer treatments, that will be **more effective**, can be used on **more patients**, provide for **quicker recovery**, and be more **affordable** for all.

And we will do this **by improving**:

**SURGERY**

*Robotic platform* that can be used independently or in concert with others

**ABLATION**

New, **more effective**, less invasive, safer form of tissue ablation: **histotripsy**

**RADIATION**

Beam therapy with **greater control, no toxicity**, and at a much lower cost
OUR VISION

To destroy cancer without any incisions or punctures

PRESENT (INVASIVE)

PRESENT (MINIMALLY INVASIVE)

FUTURE (NON-INVASIVE)
OUR VISION

Our potential impact to all key stakeholders

PATIENTS

Outcomes and quality of life

PROVIDERS

Oncology in Top 5 contribution margin

PAYERS

Up-to 300% difference in cost of care
OUR SOLUTION

Robotically Assisted Sonic Therapy (RAST™)

Combining histotripsy with advanced robotic and visualization technology
Our Solution

Histotripsy

- High-amplitude, short-pulsing (microsecond) sound energy is directed at the targeted tissue
- Rapid expansion and collapse of micro-bubbles destroy targeted tissue at a sub-cellular level
- Capable of sub-millimeter precision
OUR SOLUTION

Robotically Assisted Sonic Therapy (RAST) using Histotripsy

Complete sub-cellular destruction of primary liver cancer (HCC)

Post treatment histology in murine model
PLAN AND TREAT UNDER REAL-TIME VISUALIZATION

Target through treatment in under 30 minutes

- Physicians use integrated planning and diagnostic transducer to target the treatment area in real time
- Physicians can contour and plan treatments to any shape and size
- The system then determines the specific treatment algorithm required for each target based on size, tissue characteristics and location
- Acoustic energy is automated and delivered via the robotic micro-positioner and dynamically changed throughout the treatment based on the prescribed plan
ADVANTAGES OF RAST™

Precision

Achieve “near perfect” ablations using RAST™

- **Treatment Depth**: 10 cm
- **Size**: 3.5 cm
- **Time**: 25 min

- No damage to overlying tissue

Ability to treat any shape and size

- Personalizing the treatment to each patient’s individual tumor size, depth, and dimension

Histology confirms very precise destruction of tissue

- Untreated tissue
- Treated tissue with complete destruction
- Cell cut in half

Histology confirms very precise destruction of tissue
ADVANTAGES OF RAST™

Rapid healing

Unlike radiation or burning, treatment areas heal very quickly

Immediate post

4 weeks post

This type of healing has the potential to change the standard of follow-up care, patient anxiety, and cost
HISTOSONICS

Histosonics Early Target Markets
Primary and Metastatic Tumors*

Global Cancer Therapy Market est.
$54.4B by 2021

Radiation $10B
Surgery $41B
Ablation $3.4B

Histosonics Early Target Markets
Kidney $937M
Liver $1.1B
Pancreas $607M

Robotics are driving a significant portion of this growth

* based on Company estimates
PROCEDURAL ROADMAP

True platform potential

<table>
<thead>
<tr>
<th>Initial</th>
<th>Mid-term</th>
<th>Long-term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>Thyroid</td>
<td>Brain</td>
</tr>
<tr>
<td>Kidney</td>
<td>Lung</td>
<td>Breast</td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
<td>GI</td>
</tr>
</tbody>
</table>

Immunotherapy
BUSINESS MODEL OPPORTUNITY

Attractive capital equipment and disposable ecosystem

- **Systems**: $450 - $975K
- **Warranties**: $45K per year
- **Transducers**: $95K each
- **Procedure Kits**: $1,500 for each procedure
- **Software Upgrades**: $25K per upgrade
- **Training Programs**: $10K per training
- **Hardware Upgrades**: $135K per upgrade
- **Service**: $12K per visit

*All dollar amounts are estimates*
BUSINESS MODEL OPPORTUNITY

U.S. system market potential = $3B

2,100 US Hospitals
(over 150 beds)

2 systems = $1,425,000 per hospital

Other Potential Opportunities

- Radiology outpatient centers
- Physician offices
- Radiation therapy centers

Total U.S. market potential for installed systems = $3B
HISTOSONICS INTELLECTUAL PROPERTY

Histotripsy is a new, novel therapy, and we own it.

- Exclusive worldwide license from the University of Michigan
- Significant portfolio covering the fundamentals of histotripsy, the device and system design, and applications and clinical work-flow
- 10 granted patents — 13 patents pending
- Exclusive rights to new technologies with key academic/industry partners
## COMPANY OBJECTIVES

### 2 year milestones

<table>
<thead>
<tr>
<th>Objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Series C to fund up-through 6-9 months of US and EU launch, targeting first US sales in Q4 2019</td>
</tr>
<tr>
<td>Completion of Next Gen System</td>
</tr>
<tr>
<td>US and EU regulatory approvals - 510(k) broad soft tissue indication • anticipate no clinical trials required, consistent with all predicates</td>
</tr>
<tr>
<td>Continue to build enterprise value through expansion of clinical, technical and IP expansion</td>
</tr>
</tbody>
</table>
OUR LEADERSHIP TEAM

MIKE BLUE: PRESIDENT, CEO, BOARD DIRECTOR
- 18 years of medical device experience and commercial leadership
- Boston Scientific, superDimension (COV), NeuWave Medical (JNJ)

FRED LEE JR., MD: SENIOR MEDICAL ADVISOR, BOARD DIRECTOR
- Professor of Radiology, Biomedical Engineering, and Urology; and the past Chief, Abdominal Imaging and Oncologic Imaging at the University of Wisconsin
- Co-founder NeuWave Medical (JNJ)

CHRISTINE GIBBONS: CO-FOUNDER, CONSULTANT
- 22 years in company formation, investing, financing and operations
- Sensicore (GE), Venture Investors’ EIR, Ardesta, Seaflower Ventures

JOSH STOPEK, PHD: VP OF R&D
- 15 years of global R&D and business development leadership
- US Surgical, Covidien, Medtronic

AKHIL TRIPATHI, PHD: (UK) VP OF GLOBAL STRATEGY
- Serial MedTech entrepreneur and innovator